Recursion Pharmaceuticals Inc (NASDAQ: RXRX) kicked off on Friday, down -2.30% from the previous trading day, before settling in for the closing price of $5.65. Over the past 52 weeks, RXRX has traded in a range of $3.79-$12.36.
Healthcare Sector giant saw their annual sales slid by -35.28% over the last five years. While this was happening, its average annual earnings per share was recorded 6.07%. With a float of $332.98 million, this company’s outstanding shares have now reached $425.48 million.
Recursion Pharmaceuticals Inc (RXRX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Recursion Pharmaceuticals Inc is 23.39%, while institutional ownership is 55.84%. The most recent insider transaction that took place on Oct 23 ’25, was worth 570,000. In this transaction Chief Executive Officer of this company sold 100,000 shares at a rate of $5.70, taking the stock ownership to the 954,229 shares. Before that another transaction happened on Oct 23 ’25, when Company’s Officer proposed sale 100,000 for $5.70, making the entire transaction worth $570,000.
Recursion Pharmaceuticals Inc (RXRX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.34 earnings per share (EPS), lower than consensus estimate (set at -0.33) by -0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.07% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 18.35% during the next five years compared to -35.28% drop over the previous five years of trading.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Trading Performance Indicators
Take a look at Recursion Pharmaceuticals Inc’s (RXRX) current performance indicators. Last quarter, stock had a quick ratio of 3.58. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 37.14.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.79, a number that is poised to hit -0.38 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Recursion Pharmaceuticals Inc (RXRX)
Analysing the last 5-days average volume posted by the [Recursion Pharmaceuticals Inc, RXRX], we can find that recorded value of 42.84 million was better than the volume posted last year of 29.42 million. As of the previous 9 days, the stock’s Stochastic %D was 10.35%.
During the past 100 days, Recursion Pharmaceuticals Inc’s (RXRX) raw stochastic average was set at 39.19%, which indicates a significant increase from 21.33% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.57 in the past 14 days, which was higher than the 0.39 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.26, while its 200-day Moving Average is $5.74. Now, the first resistance to watch is $5.70. This is followed by the second major resistance level at $5.88. The third major resistance level sits at $6.03. If the price goes on to break the first support level at $5.37, it is likely to go to the next support level at $5.23. Now, if the price goes above the second support level, the third support stands at $5.05.
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) Key Stats
The company with the Market Capitalisation of 2.40 billion has total of 434,152K Shares Outstanding. Its annual sales at the moment are 58,840 K in contrast with the sum of -463,660 K annual income. Company’s last quarter sales were recorded 19,220 K and last quarter income was -171,900 K.
